Medical/Pharmaceuticals
MATELASER Launches W1 REGEN Series -- The World's Lightest Wearable Medical-Grade Cold Laser for Deep Tissue Healing
MIAMI, Fla., Nov. 14, 2025 /PRNewswire/ -- MATELASER, INC., an FDA-certified U.S. manufacturer of therapeutic laser systems, today announced the crowdfunding debut of its W1 REGEN Series, including W1 REGEN and W1 REGEN ULTRA. Weighing only 24 grams per module, the W1 REGEN is the world's lightes...
2025-11-15 00:00
2519
PRISM BioLab Achieved Initial Milestone and Receives the Milestone Payment in Drug Discovery Collaboration with Ono Pharmaceutical Co., Ltd.
TOKYO, Nov. 14, 2025 /PRNewswire/ -- PRISM BioLab, Co. Ltd. ("PRISM") announces that today, PRISM and Ono Pharmaceutical Co., Ltd. (Headquarters:Osaka; President and COO:Toichi Takino; hereinafter "Ono") have achieved the initial milestone in the drug discovery collaboration and PRISM has confirm...
2025-11-14 16:00
808
Smartee Demonstrates World-Class Manufacturing Capacity to Support Global Growth
SHANGHAI, Nov. 14, 2025 /PRNewswire/ -- Smartee Denti-Technology has showcased its world-class production system, designed to meet the increasing demand for its clear aligner products across the globe. With cutting-edge technology and robust manufacturing capabilities, Smartee supports its global...
2025-11-14 14:44
579
Datasea Reports First Quarter Gross Profit of $1.2 Million, a 4.9x Increase Year-Over-Year in its Strategy to Achieve High-Tech Product Profitability
Gross Margin Rose to 8.5% through High-Tech Products Mix and Cost Efficiencies BEIJING, Nov. 13, 2025 /PRNewswire/ -- Datasea Inc. (Nasdaq: DTSS) ("Datasea" or the "Company"), aNevada-based high-tech enterprise engaged in acoustic technologies and AI multimodal digitalization, today announces its...
2025-11-13 22:31
2865
LISCure Expands Global Partnerships for BBB Shuttle Platform 'ExoPN-101'; Signs Fourth MTA with Leading Pharma Partner
SEOUL, South Korea, Nov. 13, 2025 /PRNewswire/ -- LISCure Biosciences ("LISCure"), a biotechnology company advancing next-generation therapeutics, today announced that it has entered into a new Material Transfer Agreement (MTA) with a leading global pharmaceutical company for its proprietary blo...
2025-11-13 21:00
822
Medical AI Company VUNO Reports Profit in Q3, Driven by DeepCARS Growth
- 11 Consecutive Quarters of Revenue Growth; Q3 Revenue Exceeds KRW 10 billion for the First Time SEOUL, South Korea, Nov. 12, 2025 /PRNewswire/ -- VUNO Inc., a global medical AI company, announced that it was profitable in the third quarter of 2025, recording consolidated revenue ofKRW 10.8 bil...
2025-11-13 09:47
803
Medit and OraQ Announce Strategic Partnership to Advance AI-Driven Intelligence in Digital Dentistry
Collaboration unites two leaders in innovation to redefine how clinical insight is delivered across the dental ecosystem NEWPORT BEACH, Calif., Nov. 12, 2025 /PRNewswire/ -- Medit, a global leader in 3D intraoral scanning solutions, and OraQ, a pioneer in AI-powered clinical intelligence, today ...
2025-11-12 21:00
932
EirGenix Signed The Commercial Licensing Agreement for Its Second HER2 Biosimilar Asset EG1206A
TAIPEI, Nov. 12, 2025 /PRNewswire/ -- EirGenix Inc.(TWSE: 6589) today announced that it has entered into a second global exclusive licensing agreement with international biosimilar leader Sandoz AG (SIX:SDZ/OTCQX:SDZNY) for the commercialization of its independently developed breast cancer biosim...
2025-11-12 20:47
1211
CureGene Unveils Groundbreaking Preclinical Data for CG-0416, a Novel Oral Non-GLP-1 Therapy, at Obesity Week 2025
CG-0416, a highly liver-targeted THR-β agonist, demonstrates high-quality weight loss by reducing fat mass while preserving muscle, both as a monotherapy and in combination withGLP-1 RAs. ATLANTA, Nov. 11, 2025 /PRNewswire/ -- CureGene Pharmaceuticals ("CureGene") today announced the first discl...
2025-11-12 06:24
1890
Mabwell's Novel Anti‑IL‑11 Monoclonal Antibody 9MW3811 Approved by NMPA to Initiate Phase II Clinical Trial in Pathological Scarring
SHANGHAI, Nov. 11, 2025 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with entire industry chain, announced that its novel anti‑IL‑11 monoclonal antibody 9MW3811 has received approval from the China National Medical Products Administration (NMPA) to initiate...
2025-11-11 22:00
1045
From Bangkok to the World: Aura Bangkok Clinic Showcases International Standards in Aesthetic Care
BANGKOK, Nov. 11, 2025 /PRNewswire/ -- Aura Bangkok Clinic, a leader in Thailand's medical aesthetic industry, is enhancing the country's reputation as a top destination for Thai beauty medical tourism through its global expertise, award-winning services, and internationally recognized training p...
2025-11-11 22:00
827
Strategic Partnership Between Sanyou Bio and Yugong Bio to Accelerate Expansion in High-End Synthetic Enzyme Market
SHANGHAI, Nov. 11, 2025 /PRNewswire/ -- Sanyou Bio and Yugong Bio today announced the signing of a strategic cooperation agreement. This powerful alliance marks a significant step to deepen their collaboration in the development of high-end synthetic molecular enzymes. This collaboration is base...
2025-11-11 22:00
997
Coreline Soft Selected as Exclusive AI Provider for France's National Lung Cancer Screening Pilot Project, IMPULSION
- APHP-led IMPULSION project secures Coreline Soft as sole AI supplier
- UGAP (France's central public procurement agency) registration completed,
opening opportunities withFrance's largest public hospitals
SEOUL, South Korea, Nov. 11, 2025 /PRNewswire/ -- Coreline Soft
2025-11-11 21:00
857
MGI Tech Joins Forces with SAMRC and DSTI to Launch South Africa's 110K Human Genome Program and Unveil Africa's First DNBSEQ-T7, Ushering a New Era in African Genomics
CAPE TOWN, South Africa, Nov. 11, 2025 /PRNewswire/ -- MGI Tech Co., Ltd., a company dedicated to developing core tools and technologies that drive innovation in life sciences, today announced two historic milestones in African genomics: the official unveiling of the continent's first DNBSEQ-T7 s...
2025-11-11 17:40
971
Tiumbio to Present First Clinical Data for Dual TGF-β/VEGF Inhibitor Tosposertib (TU2218) at SITC 2025, "Robust Response Rate"
* 70.6% Partial Response and 82.4% Disease Control Rate Observed in Interim Phase II Data SEONGNAM, South Korea, Nov. 10, 2025 /PRNewswire/ -- On Friday, 7 November (local time) at the Society for Immunotherapy of Cancer (SITC) 2025 annual meeting, Tiumbio Co., Ltd. (KOSDAQ: 321550), a clinical...
2025-11-10 21:00
1270
Fapon to Showcase Innovative Molecular Diagnostic Solutions at AMP 2025 Annual Meeting & Expo
BOSTON, Nov. 10, 2025 /PRNewswire/ -- Fapon, a globally leading life sciences organization, will exhibit at the AMP 2025 Annual Meeting & Expo duringNovember 11-15 in Boston, presenting its cutting-edge enzymes for molecular diagnostics that power qPCR/RT-qPCR, Isothermal Amplification, and Next-...
2025-11-10 20:30
937
Simcere's IL-2 Mutant Fusion Protein SIM0278 Entered Phase II Clinical Trial Stage
NANJING, China, Nov. 10, 2025 /PRNewswire/ -- Simcere Pharmaceutical Group (2096.HK) announced that its regulatory T cells（Treg）-preferential IL-2 mutant Fc fusion protein (IL-2 mu-Fc), SIM0278, has officially entered a Phase II clinical study inChina for the treatment of moderate-to-severe atopi...
2025-11-10 20:06
1059
LISCure Biosciences Initiates Global Phase 2 Trial of LB-P8 in Primary Sclerosing Cholangitis (PSC)
SEOUL, South Korea, Nov. 10, 2025 /PRNewswire/ -- LISCure Biosciences
2025-11-10 20:00
804
Akeso Announces First Patient Dosed in Phase I Trial of Personalized mRNA Vaccine AK154 as Monotherapy or in Combination with Cadonilimab or Ivonescimab for Adjuvant Treatment of Pancreatic Cancer
HONG KONG, Nov. 10, 2025 /PRNewswire/ -- Akeso, Inc. (HKEX: 9926. HK) is pleased to announce that the first patient has been dosed in a Phase I clinical trial evaluating the personalized mRNA vaccine AK154. This trial is investigating AK154 both as a monotherapy and as a combination with the com...
2025-11-10 19:39
791
SanegeneBio Announces RNAi Licensing and Research Collaboration with Lilly
-Companies will collaborate on RNAi research for metabolic disease targets BOSTON, Nov. 8, 2025 /PRNewswire/ -- SanegeneBio, a clinical-stage biotechnology company developing innovative RNAi therapeutics, today announced a global research and licensing collaboration with Eli Lilly and Company ("...
2025-11-08 18:00
1259
Week's Top Stories
Most Reposted
SGTraDex and IMDA Receive Pro-Enterprise Impact & Partnership Award for Interoperable Digital Documents Against Payment Trade Cooperation
[Picked up by 313 media titles]
2025-11-25 15:37
Senetas and Nokia Announce Strategic Alliance to Secure Mission-Critical Networks for Defence and Government
[Picked up by 311 media titles]
2025-11-27 07:25SpeQtre, the entanglement-based quantum comms demonstrator satellite, is now on orbit
[Picked up by 290 media titles]
2025-11-29 09:00
HOTEL GROOVE SHINJUKU strengthens its services for deaf and hard of hearing guests
[Picked up by 288 media titles]
2025-11-25 10:00
Pop the 90s: The Westin Surabaya and Four Points Pakuwon Indah Welcomes 2026 with a Spectacular Live Show Featuring Project Pop
[Picked up by 284 media titles]
2025-11-26 10:49
Most Read
LightInTheBox to Hold 2025 Annual General Meeting on December 19, 2025
2025-11-25 21:20
2561
STAGWELL (STGW) REVEALS NEW SINGAPORE HUB TO POWER AI-DRIVEN GROWTH AND INNOVATION ACROSS APAC
2025-11-24 13:30
2256
Qudian Inc. Reports Third Quarter 2025 Unaudited Financial Results
2025-11-24 18:00
2127
NYSE Content Advisory: Pre-Market Update + Exzeo Celebrates Recent IPO
2025-11-24 21:56
2117